Home › Cancer (all types) › Maryland
Cancer (all types) clinical trials in Maryland
69 studies for Cancer (all types) are looking for participants at sites in Maryland.
Cities in Maryland
Evaluation for NCI Surgery Branch Clinical Research Protocols
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT00001823Clinical and Genetic Studies of Li-Fraumeni Syndrome
- National Cancer Institute - Shady Grove, Bethesda
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Oct 2, 2026 · NCT01443468Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
4 Weeks · All sexes · Updated Oct 2, 2026 · NCT01109394Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Oct 2, 2026 · NCT06885697Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 3 and older · All sexes · Updated Oct 2, 2026 · NCT01441089Tumor Related Epilepsy
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 8 to 99 · All sexes · Updated Oct 2, 2026 · NCT02639325A Natural History Study of Metabolic Sizing in Health and Disease
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 2 to 99 · All sexes · Updated Oct 1, 2026 · NCT05398783A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
- Greater Baltimore Medical Center ( Site 1104), Baltimore
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07209111Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 2 and older · All sexes · Updated Sep 30, 2026 · NCT00026884uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
- Chesapeake Urology, Baltimore
- Johns Hopkins Medical Center, Baltimore
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05874921Registry Study for Radiation Therapy Outcomes
- Maryland Proton Treatment Center, Baltimore
RecruitingObservational study
All ages · All sexes · Updated Sep 29, 2026 · NCT01255748Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 18 to 99 · All sexes · Updated Sep 28, 2026 · NCT07416188Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Sep 28, 2026 · NCT00006518Collection of Blood From Patients With Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT00034216Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 2 and older · All sexes · Updated Sep 28, 2026 · NCT00033137Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Sep 28, 2026 · NCT04449549A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
- Investigative Site, Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06881992Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- Johns Hopkins University, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07195591A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- JHU Oncology Central Kit Services, Baltimore
- Johns Hopkins Hospital, Baltimore
- Oncology Investigational Drug Service (IDS), Baltimore
- and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06989437A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- University of Maryland Medical System - University of Maryland Medical Center, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06901531Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 85 · All sexes · Updated Sep 24, 2026 · NCT03986034Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 23, Baltimore
RecruitingPhase 3
Ages 18 to 71 · All sexes · Updated Sep 23, 2026 · NCT075044585-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Sep 22, 2026 · NCT03366116Prospective Study to Assess a Diagnostic Aid for Cancer
- Velocity Clinical Research, Annapolis
RecruitingObservational study
Ages 45 and older · All sexes · Updated Sep 21, 2026 · NCT07046260Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore
- Sidney Kimmel Comp Cancer Center at Johns Hopkins, Baltimore
RecruitingPhase 2/3
All ages · All sexes · Updated Sep 18, 2026 · NCT03435796Collection of Tissue Samples for Cancer Research
- Johns Hopkins University, Baltimore
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
2 Months · All sexes · Updated Sep 16, 2026 · NCT00900198Evaluation of Late Effects and Natural History of Disease in Patients Treated With Radiotherapy
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Sep 16, 2026 · NCT00026650RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Sunstone Therapies, PC, Rockville
- Sheppard Pratt, Towson
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 15, 2026 · NCT07002034A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05123482Longitudinal Studies of Patient With FPDMM
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
1 Day – 100 Years · All sexes · Updated Sep 11, 2026 · NCT03854318Sample Collection and Tracking for the Developmental Therapeutics Clinic
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Sep 8, 2026 · NCT03269578A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Johns Hopkins Bayview Medical Center, Baltimore
- USO - Maryland Oncology Hematology, Columbia
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06119581A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
- University of Maryland, Baltimore
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06163534Rare Tumors and Cancer Predisposition in Individuals and Families
- National Institutes of Health Clinical Center, Bethesda
- NIH National Cancer Institute - Shady Grove, Rockville
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Sep 2, 2026 · NCT05350761Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- The Center for Cancer and Blood Disorders a division of American Oncology Partners, P.A., Bethesda
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06072612Psychological Benefits of a Normalized Camping Experience for Children With Cancer
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 7 to 25 · All sexes · Updated Aug 28, 2026 · NCT00001186A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1/2
Ages 15 and older · All sexes · Updated Aug 28, 2026 · NCT05588141Project: Every Child for Younger Patients With Cancer
- University of Maryland/Greenebaum Cancer Center, Baltimore
- Sinai Hospital of Baltimore, Baltimore
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
- and 1 more
RecruitingObservational study
Up to age 25 · All sexes · Updated Aug 25, 2026 · NCT02402244Abatacept in Immune Checkpoint Inhibitor Myocarditis
- Johns Hopkins, Baltimore
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT05335928FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.